[
  {
    "ts": "2026-02-13T12:42:14+00:00",
    "headline": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
    "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
    "url": "https://www.medicaldevice-network.com/news/novocure-stock-rises-37-on-fda-clearance-of-pancreatic-cancer-treatment-device/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "9294f718-207a-3206-8ae9-b963bd9b15bb",
      "content": {
        "id": "9294f718-207a-3206-8ae9-b963bd9b15bb",
        "contentType": "STORY",
        "title": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
        "description": "",
        "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
        "pubDate": "2026-02-13T12:42:14Z",
        "displayTime": "2026-02-13T12:42:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N2CSixWLULrZP9LciEdz1w--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p6tWyqfUhuRd5_mDiaIBzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/47ce25ff087dc098b12a2ae98de8fbd8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/novocure-stock-rises-37-on-fda-clearance-of-pancreatic-cancer-treatment-device/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novocure-stock-rises-37-fda-124214725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVCR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T12:13:52+00:00",
    "headline": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
    "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
    "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2d0db039-e2d5-3a4f-97b2-0483c9298c82",
      "content": {
        "id": "2d0db039-e2d5-3a4f-97b2-0483c9298c82",
        "contentType": "STORY",
        "title": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
        "pubDate": "2026-02-13T12:13:52Z",
        "displayTime": "2026-02-13T12:13:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-glp-121352404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T11:21:51+00:00",
    "headline": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
    "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
    "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "db7f77ae-17ba-3819-9d72-c8dd30ccbc8f",
      "content": {
        "id": "db7f77ae-17ba-3819-9d72-c8dd30ccbc8f",
        "contentType": "STORY",
        "title": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
        "description": "",
        "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
        "pubDate": "2026-02-13T11:21:51Z",
        "displayTime": "2026-02-13T11:21:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84",
          "originalWidth": 800,
          "originalHeight": 526,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J46cHXFeiV.KCDB1bvBXnw--~B/aD01MjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84.cf.webp",
              "width": 800,
              "height": 526,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M5ZSOeqVBAjq_1jRNkUlxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/34db269823393a0d4055ae912a981c84.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-us-could-action-including-110506676.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:24:00+00:00",
    "headline": "Elanco Announces Updates to Board of Directors",
    "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
    "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b32b295d-f602-3378-b2eb-67620a28f444",
      "content": {
        "id": "b32b295d-f602-3378-b2eb-67620a28f444",
        "contentType": "STORY",
        "title": "Elanco Announces Updates to Board of Directors",
        "description": "",
        "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
        "pubDate": "2026-02-13T14:24:00Z",
        "displayTime": "2026-02-13T14:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7",
          "originalWidth": 400,
          "originalHeight": 267,
          "caption": "Elanco logo (PRNewsfoto/Elanco Animal Health)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YVlah8Of7uCdH0.E7W3ozw--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7.cf.webp",
              "width": 400,
              "height": 267,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jQVWGyXDrcoazxzeSZz1MA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a311ae0d2c70e9652fafd66dc89a71d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/elanco-announces-updates-board-directors-142400658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELAN"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:35:00+00:00",
    "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
    "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
    "url": "https://www.fool.com/investing/2026/02/13/did-eli-lilly-just-make-deal-for-next-blockbuster/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c55e5da2-da7d-38b1-8415-cbe8cd85f7e8",
      "content": {
        "id": "c55e5da2-da7d-38b1-8415-cbe8cd85f7e8",
        "contentType": "STORY",
        "title": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
        "description": "",
        "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
        "pubDate": "2026-02-13T15:35:00Z",
        "displayTime": "2026-02-13T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Scientists in a medical lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zYWf2wls7.7UM_d9KTtedg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3xIBXFCN6qGQmoUWeOxsBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/13/did-eli-lilly-just-make-deal-for-next-blockbuster/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lilly-just-deal-153500397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:28+00:00",
    "headline": "Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical research stocks to buy according to hedge funds. On February 10, Eli Lilly and Company (NYSE:LLY) was upgraded to Buy from Hold by Freedom Capital, with the firm raising the price target on the stock to $1,200 from $1,050. The rating update came after […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gets-145728610.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "40e5f597-58ee-3c73-92d4-04d9e46ac145",
      "content": {
        "id": "40e5f597-58ee-3c73-92d4-04d9e46ac145",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical research stocks to buy according to hedge funds. On February 10, Eli Lilly and Company (NYSE:LLY) was upgraded to Buy from Hold by Freedom Capital, with the firm raising the price target on the stock to $1,200 from $1,050. The rating update came after […]",
        "pubDate": "2026-02-13T14:57:28Z",
        "displayTime": "2026-02-13T14:57:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gets-145728610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-gets-145728610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:54:44+00:00",
    "headline": "Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections. Eli Lilly & Company (NYSE:LLY) posted revenues of around $19.3 […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-retains-buy-145444712.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8aa88797-b393-384c-87cf-0a74d5837f08",
      "content": {
        "id": "8aa88797-b393-384c-87cf-0a74d5837f08",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook",
        "description": "",
        "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections. Eli Lilly & Company (NYSE:LLY) posted revenues of around $19.3 […]",
        "pubDate": "2026-02-13T14:54:44Z",
        "displayTime": "2026-02-13T14:54:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23",
          "originalWidth": 283,
          "originalHeight": 178,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8PhkuSOImzcJWO03ORbAAA--~B/aD0xNzg7dz0yODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 283,
              "height": 178,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LIJLTrtCu6kOCCm8Vfx83Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-retains-buy-145444712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-retains-buy-145444712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T17:24:04+00:00",
    "headline": "Eli Lilly Builds Orforglipron Inventory Ahead of FDA Review",
    "summary": "Drugmaker increases pre-launch stockpile as oral GLP-1 review approaches.",
    "url": "https://finance.yahoo.com/news/eli-lilly-builds-orforglipron-inventory-172404814.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "edafba09-37dc-3d70-9635-5e032c335384",
      "content": {
        "id": "edafba09-37dc-3d70-9635-5e032c335384",
        "contentType": "STORY",
        "title": "Eli Lilly Builds Orforglipron Inventory Ahead of FDA Review",
        "description": "",
        "summary": "Drugmaker increases pre-launch stockpile as oral GLP-1 review approaches.",
        "pubDate": "2026-02-13T17:24:04Z",
        "displayTime": "2026-02-13T17:24:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-builds-orforglipron-inventory-172404814.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-builds-orforglipron-inventory-172404814.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:50:03+00:00",
    "headline": "Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-145003504.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f55f4b6e-c7c6-3961-8742-25c4ce5d1a08",
      "content": {
        "id": "f55f4b6e-c7c6-3961-8742-25c4ce5d1a08",
        "contentType": "STORY",
        "title": "Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2026-02-13T14:50:03Z",
        "displayTime": "2026-02-13T14:50:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f",
          "originalWidth": 900,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SVlgtyKcqJmTvHzvwqjZfA--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f.cf.webp",
              "width": 900,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7KqPU5XU5bEHAxdnZQ3L5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-145003504.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-145003504.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T17:59:16+00:00",
    "headline": "Eli Lilly Builds $1.5 Billion Pill Inventory",
    "summary": "Inventory jumps ahead of Q2 nod",
    "url": "https://finance.yahoo.com/news/eli-lilly-builds-1-5-175916882.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "c2cb530b-4d85-37ee-b00b-5fb6369ffda6",
      "content": {
        "id": "c2cb530b-4d85-37ee-b00b-5fb6369ffda6",
        "contentType": "STORY",
        "title": "Eli Lilly Builds $1.5 Billion Pill Inventory",
        "description": "",
        "summary": "Inventory jumps ahead of Q2 nod",
        "pubDate": "2026-02-13T17:59:16Z",
        "displayTime": "2026-02-13T17:59:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-builds-1-5-175916882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-builds-1-5-175916882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]